| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_733f9f206a30eb241a0e7ece400747f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f41a868f49ca4f32d18d861e3afb411 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-805 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-721
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1816 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-72 |
| filingDate |
2018-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_550cf6a71af5cbae2d14b878006d12c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0500760191565b8c1cbe994b08e3193e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f830d5b9b1b9ec8b47bd19f3bfb87b98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dae364aaa585b125aa4c7cd5845699ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f59636bbd3d5d4bc998f99726396a10 |
| publicationDate |
2018-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018217166-A1 |
| titleOfInvention |
Prediction-method of mortality due to treatment with erythropoiesis stimulating agents |
| abstract |
The present invention pertains to the diagnosis of a high risk of mortality or other adverse events in a patient suffering from anemia, for example anemia caused by chemotherapy, cancer or chronic inflammation such as chronic kidney disease (CKD). The invention provides means to diagnose a patient who receives Erythropoiesis Stimulating Agents (ESA) and suffer from an adverse event if the treatment with the ESA is continued. Based on the herein disclosed methods, the clinician will be able to diagnose the prevalence of a fatal event and adjust the treatment of the anemia in the patient accordingly. |
| priorityDate |
2017-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |